Perrigo (PRGO) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.42%. A quarter ago, it was expected that this drug company would post earnings of $0.24 per share when it actually produced earnings of $0.29, delivering a surprise of 20.83%.Over the last four quarters, the company has ...

财务业绩 - 公司第二季度净销售额为11亿美元，同比下降10.7%[3] - 有机净销售额下降9.1%，主要由于婴儿配方奶粉销售下降6.8个百分点和上呼吸道及止痛睡眠类产品销售下降4.0个百分点[3] - 消费者自我护理国际业务净销售额下降2.5%，有机净销售额增长1.0%[4] - 消费者自我护理美洲业务净销售额下降15.5%，主要由于婴儿配方奶粉销售下降10.8个百分点和上呼吸道及止痛睡眠类产品销售下降4.4个百分点[5] - 调整后毛利率为40.6%，同比增加190个基点[5] - 调整后营业利润为1.39亿美元，同比增长1.5%[6] - 调整后每股收益为0.53美元，同比下降15.9%[9] - 公司维持2024财年调整后每股收益2.50-2.65美元的指引[17] - 公司预计2024财年有机净销售额将下降3%-1%，总净销售额将下降5%-3%[16] - CSCA报告净销售额6.34亿美元，同比下降15.5%，主要由于有机净销售额下降15.1%和退出产品线影响-0.4%[43] - 有机净销售额受到以下因素影响：1)婴儿配方奶粉销售下降10.8个百分点；2)上呼吸道和止痛睡眠类产品销售下降4.4个百分点，由于季节性需求下降和为提高利润率而精简SKU[44] - 报告毛利润1.9亿美元，同比下降15.5%。调整后毛利润2.01亿美元，下降12.1%，主要由于销量下降和制造费用不利吸收，部分被战略性定价和供应链优化措施抵消[45][46] - 报告营业利润0.69亿美元，同比下降29.1%。调整后营业利润0.91亿美元，下降19.9%，主要由于毛利润下降和广告促销投入增加，部分被供应链优化措施抵消[47][48] - CSCI报告净销售额4.31亿美元，同比下降2.5%，有机净销售额增长1.0%被退出产品线-1.1%和汇率影响-2.4%抵消[55] - CSCI报告毛利润2.05亿美元，增长0.7%。调整后毛利润2.31亿美元，下降0.7%，但按不变汇率计算增长1.8%，受益于定价策略、新产品和供应链优化[57][58] - CSCI报告营业亏损0.1亿美元，上年同期盈利0.09亿美元。调整后营业利润0.91亿美元，增长29.5%，主要由于广告促销投入下降和供应链优化措施[59][60] - 公司预计2024财年有机净销售额同比下降3%至1%，总净销售额下降5%至3%，主要由于上半年季节性需求下降和下半年美国自有品牌销量预期下降[62] - 公司重申2024财年调整后每股收益2.50美元至2.65美元，调整后税率约20.5%，经营活动现金流转换率约90%至100%[62] 非GAAP财务指标 - 公司提供非GAAP财务指标作为补充信息,以帮助投资者和分析师评估公司的经营趋势、便于不同期间和同行业公司的比较,以及评估公司未来的业绩[70] - 非GAAP财务指标排除了诸如减值、重组和并购整合相关费用等性质影响可比性的项目[70] - 公司认为调整后的毛利率和营业利润率对投资者有用,可以更容易地比较和分析同行业趋势,并比较公司的整体业绩[72] - 公司还披露了剔除汇率影响的有机销售增长[72] 现金流和资产负债表 - 2024年6月29日现金及现金等价物为5.428亿美元,较2023年12月31日下降27.7%[76] - 2024年6月29日存货为11.162亿美元,较2023年12月31日下降2.2%[76] - 2024年上半年经营活动产生的现金流量为0.81亿美元,上年同期为7.23亿美元[77] - 2024年上半年投资活动产生的现金流量流出0.968亿美元,上年同期流出0.24亿美元[77] 其他财务数据 - 公司报告的持续经营业务收入为10.655亿美元和11.931亿美元[2] - 公司报告的持续经营业务毛利率为37.0%和35.9%[1] - 公司报告的持续经营业务营业亏损为2650万美元和营业利润5680万美元[1] - 公司报告的持续经营业务每股摊薄亏损为0.77美元和每股摊薄收益0.06美元[1] - 公司调整后的毛利率为40.6%和38.7%[1] - 公司调整后的营业利润为1.393亿美元和1.373亿美元[1] - 公司调整后的每股摊薄收益为0.53美元和0.63美元[1] - 公司确认了3410万美元的商誉减值[3] - 公司确认了3720万美元的重组费用和其他终止福利[1] - 公司确认了2640万美元的异常诉讼费用[1] - 研发费用为2940万美元，占收入2.8%[87] - 销售、一般及管理费用为3.208亿美元，占收入30.1%[87] - 重组及其他费用为7100万美元，占收入6.7%[87] - 公司三个月期间利息及其他收益为4750万美元，占收入4.5%[93] - 公司三个月期间所得税费用为3170万美元，有效税率为-42.8%[93] 分部业绩 - 公司消费者自我护理美洲业务第二季度收入为6.341亿美元，同比下降15.5%[110] - 公司消费者自我护理国际业务第二季度收入为

Delivered Adjusted Diluted Earnings Per Share Results as Expected; Reaffirm Fiscal 2024 Adjusted Diluted EPS Outlook Progressing One Perrigo Blueprint: On Target to Deliver Project Energize Goals; Enhancing Capabilities; Completed Divestment of HRA Pharma Rare Diseases Business on July 10, 2024 DUBLIN, Aug. 2, 2024 /PRNewswire/ -- Second Quarter 2024 Highlights: Net sales of $1.1 billion declined 10.7% versus the prior year quarter. Organic1 net sales decreased 9.1%, due primarily to -6.8 percentage points ...

DUBLIN, Aug. 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on September 17, 2024, to shareholders of record on August 30, 2024.About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consum ...

DUBLIN, July 31, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Canaccord Genuity 44th Annual Growth Conference, on Wednesday, August 14 at 3:30 PM EDT. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provi ...

Perrigo Company plc (PRGO) is scheduled to report second-quarter 2024 numbers on Aug 2, before the opening bell. In the last reported quarter, the company posted an earnings surprise of 20.83%.Let’s see how things have shaped up for this announcement.Factors at PlayThe Zacks Consensus Estimate for Perrigo’s total revenues is pegged at around $1.13 billion, while the same for earnings stands at 48 cents per share. Both metrics indicate a decline from the year-ago quarter’s levels.Perrigo reports its results ...

The market expects Perrigo (PRGO) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 2, 2024, might help the stock move higher if these key numbers are better t ...

DUBLIN, July 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2024 financial results on Friday, August 2, 2024, and host a conference call beginning at 8:30 A.M. (EST).The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, In ...

DUBLIN, July 10, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that it has completed the previously announced divestment of the HRA Pharma Rare Diseases business to Esteve Healthcare, S.L. ("ESTEVE") for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million, subject to customary net debt and working capital adjustments, and up to €85 million in potential earnou ...

SEATTLE, June 24, 2024 (GLOBE NEWSWIRE) -- UNITED STATES DISTRICT COURTDISTRICT OF NEW JERSEY ROOFER’S PENSION FUND, on behalf ofitself and all others similarly situated,                        Plaintiff,        v.JOSEPH C. PAPA, et al.,                        DefendantsCase No. 1:16-cv-02805-RMB-LDWCLASS ACTION SUMMARY NOTICE OF (I) PROPOSED SETTLEMENTAND PLAN OF ALLOCATION; (II) SETTLEMENT HEARING; AND(III) MOTION FOR ATTORNEYS’ FEES AND LITIGATION EXPENSES To:(1) All persons who purchased Perrigo Compan ...